
Photo taken from Deniz Can Guven/X
Mar 16, 2024, 10:49
Deniz Can Guven: We reviewed the available evidence regarding ICI use in patients with frailty
Deniz Can Guven, Medical Oncologist at , recently shared on X/Twitter:
“Out in Journal of Geriatric Oncology.
We reviewed the available evidence regarding ICI use in patients with frailty.
Take home points:
- The available studies mostly used ECOG as a frailty surrogate.
- No increase in irAEs with frailty.
- Shortened OS in frailty-Mechanism.
- Need for more studies incorporating CGA to assess real impact.”
Source: Deniz Can Guven/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 12:41
Feb 21, 2025, 12:39
Feb 21, 2025, 11:36
Feb 21, 2025, 11:29